Clinical Research Papers:
Influence of age on predictiveness of genetic risk score for prostate cancer in a Chinese hospital-based biopsy cohort
Metrics: PDF 871 views | HTML 964 views | ?
Yao Zhu1,2,*, Cheng-Tao Han1,2,*, Hai-Tao Chen3,4,5, Fang Liu3,4,5, Gui-Ming Zhang1,2, Wei-Yi Yang1,2, Jian-Feng Xu3,4,5,6, Ding-Wei Ye1,2
1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
2Department of Oncology, Shanghai Medical Colleague, Fudan University, Shanghai, China
3Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China
4State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
5Center for Genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, China
6Center for Cancer Genomics, Wake Forest School of Medicine, Winston-Salem, NC, USA
*These authors have contributed equally to this work
Ding-Wei Ye, e-mail: email@example.com
Keywords: prostate cancer, age, genetic score, predictive performance, multivariate model
Received: February 06, 2015 Accepted: May 07, 2015 Published: May 15, 2015
Background: We investigated whether age influences the predictiveness of genetic risk score (GRS) for prostate cancer (PCa) in a Chinese hospital-based biopsy cohort.
Methods: We included consecutive patients who underwent prostate biopsies in two tertiary centers between 2012 and 2014. GRS was calculated using 24 PCa-associated genetic variants and its predictiveness was assessed by area under curve (AUC).
Results: Of 1120 men tested, 724 with prostate-specific antigen (PSA) < 20 ng/ml were selected for further analysis. Patients were divided into 3 groups by age cutoffs at 60 and 70 years. GRS significantly predicted PCa for all patients (AUC: 0.561; 95% CI: 0.514–0.609) and was an independent predictor in multivariate analysis for the 60–70 year-olds (AUC: 0.612, 95% CI: 0.541–0.684), but not for patients aged < 60 years or ≥70 years. For PCa with Gleason score ≥7, GRS discriminative ability was 0.582 (95% CI=0.527–0.637) for all patients, and 0.647 (95% CI: 0.541–0.684) for the 60–70 year-old group.
Conclusion: GRS significantly increased clinical prediction of PCa and high-grade disease in Chinese men aged 60–70 years, which implies that men in this age group would benefit most from genetic testing.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.